Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6752086 | 0.98 | MEN1 (0.53) | MEN1KMT2AEPHX1CA12CA1 | |
| SCHEMBL5638963 | 0.86 | CYP1A2 (0.56) | MEN1KMT2AEPHX1HTTATM | |
| SCHEMBL31122367 | 0.82 | HTT (0.53) | MEN1KMT2AEPHX1HTTATM | |
| SCHEMBL1128514 | 0.82 | HTT (0.53) | MEN1KMT2AEPHX1HTTATM | |
| SCHEMBL12689890 | 0.81 | CYP1A2 (0.55) | MEN1KMT2AHTTATMCYP1A2 | |
| SCHEMBL9456940 | 0.81 | LMNA (0.60) | KMT2AEPHX1CA12CA1CA2 | |
| SCHEMBL10748357 | 0.81 | HTT (0.49) | EPHX1HTTATMCYP1A2LMNA | |
| SCHEMBL1533677 | 0.78 | ALOX5 (0.53) | MEN1KMT2ACA2CYP1A2ALDH1A1 | |
| SCHEMBL12689913 | 0.78 | CYP1A2 (0.48) | MEN1KMT2AHTTATMCYP1A2 | |
| SCHEMBL1478837 | 0.77 | MEN1 (0.66) | MEN1KMT2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745456-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | The University of North Carolina at Chapel Hill: | 2008-03-06 | — | — | US | disclosed |
| US-7163955-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070010533-A1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-11 | — | — | US | disclosed |
| US-20060063931-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-23 | — | — | US | disclosed |
| US-RE37438-E1 | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. | 2001-11-06 | — | — | US | disclosed |
| US-5866612-A | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. (US) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063931-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | MEN1 4855/4885KMT2A 4802/4885EPHX1 1546/4885 |
| US-20070010533-A1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | OAT, GYS2, HCCS | MEN1 4855/4885KMT2A 4802/4885EPHX1 1546/4885 |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | TLR7, DHRS9, TLR8 | MEN1 2949/4885KMT2A 3769/4885EPHX1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.